Key result
SGLT2i and GLP-1 RAs offer cardiometabolic benefits to stroke survivors with T2D, HF, or CKD.
Why the study?
SGLT2 inhibitors and GLP-1 receptor agonists are not currently included in secondary stroke prevention guidelines, despite growing evidence suggesting they may improve long-term, stroke-related outcomes.
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in stroke survivors with comorbid type 2 diabetes, heart failure, chronic kidney disease, or obesity to reduce subsequent cardiovascular risk, despite not yet being included in secondary stroke prevention guidelines.
Post-stroke SGLT2i/GLP-1RA use may lower CV risk; leaves open confirmation in randomized trials.
Stroke is a multifactorial cardiovascular disease (CVD), which predominantly affects older adults. Consequently, cardiovascular risk factors and related comorbidities are highly prevalent among people presenting with acute stroke. These conditions, and the stroke event itself, may require specific pharmacological therapies to reduce subsequent risk. Over recent decades, two novel pharmacological drug classes, sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, which were initially developed as glucose-lowering therapies for type 2 diabetes mellitus, have been used for management of related cardiovascular conditions. These agents are not currently included in secondary stroke prevention guidelines, despite growing evidence suggesting that they may directly or indirectly improve long-term, stroke-related outcomes. It is therefore essential that the stroke community remains up-to-date with these developments while awaiting updated clinical guidelines. This will ensure optimal management of coexisting cardiovascular disease and reduce subsequent risk. In this commentary, we summarize and discuss what we consider to be the most relevant and impactful recent studies for contemporary clinical stroke practice.
No takes yet. Share an insight, caveat, or question.
Ihle‐Hansen et al. (2026) conducted a review in Stroke with cardiovascular comorbidities (T2DM, CKD, HF). SGLT2 inhibitors and GLP-1 receptor agonists was evaluated. SGLT2 inhibitors and GLP-1 receptor agonists offer significant cardiometabolic benefits and should be considered in stroke survivors with comorbid type 2 diabetes, heart failure, or chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Frontiers in Stroke